科伦药业：子公司核心产品博度曲妥珠单抗治疗2L+HER2+乳腺癌获批上市

Core Viewpoint - Kelong Pharmaceutical's subsidiary, Kelong Botai, received approval for its HER2-targeted antibody-drug conjugate, Boduocutuzumab (舒泰莱®), for treating adult patients with HER2-positive breast cancer who have previously received one or more anti-HER2 therapies [2] Group 1 - The drug Boduocutuzumab has shown significant statistical and clinical improvement in progression-free survival (PFS) compared to T-DM1 in a pre-specified interim analysis [2] - There is a trend observed in the overall survival (OS) benefit for Boduocutuzumab [2] - Kelong Botai has initiated a Phase II open-label, multicenter clinical study for Boduocutuzumab in patients with HER2-positive, unresectable, or metastatic breast cancer who have previously received effective payloads of topoisomerase inhibitor ADC therapy [2]